1. Scrip
  2. >>Business

AbbVie Gains Lung Cancer ADC, Solid Tumor Platform With Stemcentrx Buyout

 
• By Joseph Haas

As part of its strategy to offset the coming Humira patent cliff, AbbVie Inc. is looking to oncology as a "significant pillar of growth" going forward, a gambit CEO Richard Gonzalez says will benefit greatly from both the pipeline candidates and the solid tumor R&D engine his company will obtain in the $5.8bn purchase of Stemcentrx announced April 28.

The transaction was unveiled in tandem with AbbVie's first quarter earnings call, during which the company reported an 18.2% year-over-year increase in net revenues to $5.96bn, with Humira (adalimumab) up 14.9% to $3.58bn. (Also see "Humira Competition Dominates AbbVie Earnings" - Scrip, 1 February, 2016.) The firm's hematology asset Imbruvica (ibrutinib), partnered with Johnson & Johnson, posted what Gonzalez termed "strong growth" to $381m on the quarter. J&J reported first quarter sales of $281m worldwide, up from $116m in the year-ago quarter. (Also see " JnJ Not Sweating Remicade Biosimilar Approval " - Scrip, 20 April, 2016.)

AbbVie hopes to continue its oncology expansion with the Stemcentrx play. The firm agreed to pay $2bn in cash and $3.8bn in stock for Stemcentrx, making it one of the highest valuations ever for a venture-backed biotech takeout, along with up to $4bn in regulatory and clinical development milestones to Stemcentrx shareholders

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.